Adherence to Dipeptidyl Peptidase-4 Inhibitors or Biguanidesand Associating Factors Related to Adherence in Patients with Type 2 Diabetes Mellitus: Observational, Cross-Sectional, Pharmacy-Based Survey

Adherence to Dipeptidyl Peptidase-4 Inhibitors or Biguanidesand Associating Factors Related to Adherence in Patients with Type 2 Diabetes Mellitus: Observational, Cross-Sectional, Pharmacy-Based Survey - Adherence to Dipeptidyl Peptidase-4 Inhibitors or Biguanidesand Associating Factors Related to Adherence in Patients with Type 2 Diabetes Mellitus: Observational, Cross-Sectional, Pharmacy-Based Survey

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026466

Enrollment

845

Registered

2017-04-01

Start date

2017-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosed with T2DM Receiving medical treatment at clinics/hospitals in Japan The patients themselves who are currently prescribed DPP-4i (QD or BID) or biguanide (BID, 1 pill at a time) as monotherapy for at least last prescription period Having such a drug at an identical pharmacy with at least more than 30 day-prescription in the last visit The patient able to read, write, and smoothly communicate in Japanese Providing informed consent

Exclusion criteria

Exclusion criteria: Pregnant at any time of the study period Type 1 diabetes Prescribed DPP-4i (QW) or biguanide (other than BID with 1 pills at a time) Taking any other concomitant medications including prescribed oral drug or injectable drugs,during the last prescription period of DPP-4i (OD or BID) or biagunide BID, 1 pill at a time)

Design outcomes

Primary

Measure	Time frame
Adherence measured as the numbers of days missed any dose(s) during the 7 days prior to the survey	—

Secondary

Measure	Time frame
Adherence measured as the numbers of days missed any dose(s) during the 30 days prior to the survey	—

Countries

Japan

Contacts

Public ContactTakekazu Kubo

MSD K.K. Medical Affairs

ldgproject@merck.com03-6272-2338

Outcome results